Back to Article List

Commission authorizes human‐identical milk oligosaccharide as a novel food

European Union

May 18, 2023

The NF is mainly composed of the human‐identical milk oligosaccharide (HiMO) 6′‐SL but also contains D‐lactose, sialic acid and a small fraction of other related oligosaccharides. The NF is produced by fermentation with a genetically modified strain of Escherichia coli K‐12 DH1. The information provided on the manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF in a variety of foods, including infant and follow‐on formula, foods for infants and toddlers, foods for special medical purposes and food supplements. The target population is the general population. The anticipated daily intake of 6′‐SL from the NF at the maximum proposed use levels is unlikely to exceed the intake level of naturally occurring 6′‐SL in breastfed infants on a body weight basis. The intake of 6′‐SL in breastfed infants on a body weight basis is expected to be safe also for other population groups. The intake of other carbohydrate‐type compounds structurally related to 6′‐SL is also considered of no safety concern. Food supplements are not intended to be used if other foods with the added NF or breast milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.


Cf. Commission Implementing Regulation (EU) 2023/948 of 12 May 2023 authorising the placing on the market of 6′-Sialyllactose sodium salt produced by derivative strains of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470.



For further information (in English), click on the Link

Related Articles
See All News
Subscribe to our newsletter

The best industry insight in your mailbox